Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non‐small cell lung cancer

Abstract

This oxaliplatin and gemcitabine schedule has shown activity in advanced NSCLC with modest toxicity. Neither clinical nor PK outcomes were influenced by the sequencing of these agents, although definite conclusions are limited by small patient numbers. The favorable toxicity profile of this doublet, in light of an encouraging RR, warrants its further investigation in NSCLC.